(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

INTRODUCTION: Prostate specific membrane antigen (PSMA), highly expressed in metastatic castration-resistant prostate cancer (mCRPC), is an established therapeutic target. Theranostic PSMA-targeting agents are widely used in patient management and has shown improved outcomes for mCRPC patients. Earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouzayed, Ayman, Seitova, Kamila, Lundmark, Fanny, Bodenko, Vitalina, Oroujeni, Maryam, Tolmachev, Vladimir, Rosenström, Ulrika, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565663/
https://www.ncbi.nlm.nih.gov/pubmed/37829345
http://dx.doi.org/10.3389/fonc.2023.1221103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565663/
https://www.ncbi.nlm.nih.gov/pubmed/37829345
http://dx.doi.org/10.3389/fonc.2023.1221103

Ejemplares similares